All individual trials at National Institute of Allergy and Infectious Diseases (NIAID)
Trials reported
133 out of 137
Percent reported
97.1%
US Govt could have imposed fines of at least
$99,967,729
Fines claimed by US Govt
$0
Showing 1 to 100 of 232 entries
| Status | Sponsor | Trial ID | Title | Completion date | Days overdue |
|---|---|---|---|---|---|
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02921997 | A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses [pACT] | 2017-03-28 | 579 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02178800 | A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women [pACT] | 2017-04-05 | 25 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT00023504 | Evaluation of Immune Response to Vaccines in Primary Immune Disorders [pACT] | 2017-05-22 | 1413 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02029638 | Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST) [pACT] | 2017-09-06 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02629094 | Cardiometabolic Effects of Eplerenone in HIV Infection [pACT] | 2017-09-11 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT00865566 | Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men [pACT] | 2017-10-06 | 2 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01404312 | Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection [pACT] | 2017-11-14 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01314911 | A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults [pACT] | 2017-11-18 | 54 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01999868 | Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI) [pACT] | 2017-12-07 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02709005 | A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis [pACT] | 2017-12-11 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02363322 | A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection [pACT] | 2017-12-31 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02475655 | A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults [pACT] | 2018-02-18 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02562482 | Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults [pACT] | 2018-03-06 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02260934 | Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI) [pACT] | 2018-03-12 | 1 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01933594 | A Phase I/II Study of Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression [pACT] | 2018-04-16 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02572817 | A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A [pACT] | 2018-04-26 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT00950248 | Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis [pACT] | 2018-04-30 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02194998 | Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT) [pACT] | 2018-05-17 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01436357 | A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut [pACT] | 2018-05-25 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01086540 | A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) [pACT] | 2018-06-05 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02287467 | Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG) [pACT] | 2018-06-07 | 105 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02663674 | A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever) [pACT] | 2018-06-21 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01552369 | Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients [pACT] | 2018-06-22 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01867671 | Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD) [pACT] | 2018-07-02 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01504841 | A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years [pACT] | 2018-07-17 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02996448 | A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome [pACT] | 2018-07-22 | 336 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT00890162 | A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis [pACT] | 2018-07-31 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02404311 | A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection [pACT] | 2018-08-07 | 411 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03596151 | Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs | 2018-08-20 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03249935 | Treatment Failure and Associated Predictors Following Azithromycin Treatment for Urogenital Chlamydial Infection in Males in Youth Correctional Facilities | 2018-09-17 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01854359 | Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis [pACT] | 2018-10-31 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02371668 | Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model [pACT] | 2018-11-30 | 19 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03382834 | Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors | 2018-12-04 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03058692 | A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine | 2019-01-14 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02766023 | Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis [pACT] | 2019-02-11 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02237196 | Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD) [pACT] | 2019-03-04 | 14 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02651259 | A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection | 2019-04-10 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02282904 | Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Post-Transplant Cyclophosphamide [pACT] | 2019-04-10 | 3 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03151148 | A First in Man Evaluation of the Safety and Efficacy of an Allogeneic Targeted Microbiome Transplant in Adults With Moderate-to-Severe Atopic Dermatitis (ADRN-08) | 2019-05-14 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01595529 | Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" [pACT] | 2019-06-30 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02266888 | B Cell Targeted Induction to Improve Outcomes in Pediatric Lung Transplantation (CTOTC-08) [pACT] | 2019-06-30 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01946880 | An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE) [pACT] | 2019-07-03 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02293837 | Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI) [pACT] | 2019-07-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03369951 | A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN) | 2019-07-20 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03318315 | A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine | 2019-07-25 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02915016 | A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants [pACT] | 2019-08-07 | 3 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02199496 | An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency [pACT] | 2019-08-16 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03719586 | A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease | 2019-09-09 | 112 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03312231 | A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant | 2019-09-26 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03110770 | VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents | 2019-10-04 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03018275 | Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Phase I/II | 2019-10-11 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02081638 | Elite Controller and ART-Treated HIV+ Statin Versus ASA Treatment Intervention Study [pACT] | 2019-10-16 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03697993 | Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS) | 2019-10-24 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02519777 | A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV [pACT] | 2019-12-02 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03852316 | Pivotal Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women | 2019-12-02 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02385123 | Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers [pACT] | 2019-12-06 | 445 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03284710 | A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants | 2019-12-12 | 2 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02891915 | A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP) [pACT] | 2019-12-16 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02474199 | Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12) [pACT] | 2019-12-16 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03845231 | Mucosal Correlates of Protection After Influenza Viral Challenge of Vaccinated and Unvaccinated Healthy Volunteers | 2019-12-20 | 78 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02876328 | Partnership for Research on Ebola VACcinations (PREVAC) | 2019-12-24 | 567 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01649869 | A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss [pACT] | 2019-12-24 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03328325 | Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on the B Cell Response to Inactivated Influenza Vaccine in Healthy Adults and Children | 2020-02-09 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02533180 | Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults (ITN056ST) [pACT] | 2020-02-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03341273 | Targeted Reduction of Antibiotics Using Procalcitonin in a Multi-center, Randomized, Double-Blinded, Placebo-Controlled Non-Inferiority Study of Azithromycin Treatment in Outpatient Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin (PCT) Level of < / = 0.25 ng/mL (TRAP-LRTI) | 2020-03-30 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02485639 | Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination [pACT] | 2020-03-31 | 274 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03389893 | Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study | 2020-04-03 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02496676 | A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients With XMEN Syndrome [pACT] | 2020-04-23 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03682120 | A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant | 2020-04-30 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02720094 | A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men [pACT] | 2020-05-14 | 503 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03541499 | A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults | 2020-05-15 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04280705 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults | 2020-05-21 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02130882 | A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES) [pACT] | 2020-06-01 | 154 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03589807 | A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A/H7N9 Inactivated Influenza Vaccines Administered Intramuscularly With or Without AS03 Adjuvant in Healthy Adults 19-50 Years of Age | 2020-06-14 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03208231 | Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 With Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants | 2020-06-16 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03738241 | A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects | 2020-06-19 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03589768 | A Phase II Double-Blind Trial to Evaluate the Safety, Immunogenicity and Effect on Infant Immune Responses of a Single Dose of Tdap in Pregnant Women in Mali | 2020-07-01 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04358068 | A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 2020-07-08 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03122223 | A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants | 2020-07-30 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04401579 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2) | 2020-07-31 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03787095 | Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: A Phase I/II, Double-blind, Placebo-controlled, Ascending Multiple Dose Study | 2020-08-18 | 1 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03332095 | Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents | 2020-08-19 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02818582 | PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen [pACT] | 2020-08-31 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03048422 | Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants | 2020-10-03 | 1 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02231879 | A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome. [pACT] | 2020-10-08 | 76 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03164564 | A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women | 2020-11-05 | 138 |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03301415 | A Phase II, Single Stage, Single-Arm Investigation of Oral Valganciclovir Therapy in Infants With Asymptomatic Congenital Cytomegalovirus Infection | 2020-11-05 | 389 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03978091 | A Phase 1, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ(R) in Combination With Aztreonam (COMBINE) | 2020-11-23 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02716675 | A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men [pACT] | 2020-12-01 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01524536 | Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes [pACT] | 2020-12-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04492475 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3) | 2020-12-21 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03548051 | Phase 1/2 Placebo Controlled, Partially-Blinded Clinical Trial to Assess the Safety and Efficacy of Microbial Restoration by Enema With Banked and Thawed Processed Stool in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) | 2021-01-13 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT01302847 | Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents [pACT] | 2021-01-20 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT05780268 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H1: LY3819253 (LY-CoV555)) | 2021-02-01 | 535 |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03560258 | HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy | 2021-02-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03952650 | Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali | 2021-02-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT02736968 | Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa [pACT] | 2021-03-10 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT03292588 | Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30) | 2021-04-20 | |
| reported | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04640168 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4) | 2021-05-18 | |
| reported-late | National Institute of Allergy and Infectious Diseases (NIAID) | NCT05780424 | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H3: BRII-196/BRII-198) | 2021-06-08 | 579 |